Facebook link Linked In link You Tube link

Interventional Immunology Online


Interventional Immunology Online View the Course Join Today

Access for FREE by
becoming a member.

Registration Rates
Join FOCIS today! Access Access with
CME credit
FOCIS Member FREE $50
Non-Member $100 Included

Instructions to Access Content

  1. Click here and click on Interventional Immunology.
  2. Click Add to Basket on the right side of the page.
  3. Click on Interventional Immunology.
  4. If you are a FOCIS member, login with your FOCIS username and password. If you are not a member, please create an account.
  5. Select if you would like access to the content only, or if you would like to claim CME credit.
  6. After submitting the order, click on Continue to My Content.
  7. Select the video to watch and pause to complete the pre-test.
  8. Click on Submit Credit at any point to print your CME certificate. Before you can print the certificate, you will be asked to complete the post-test and evaluation.

Target Audience/Purpose
The Interventional Immunology course familiarizes practicing physicians with the scientific basis of novel immune therapies, their clinical applications, and possible side-effects and limitations. The content of this webinar was captured during the live Interventional Immunology course, June 24, 2011 in Washington, D.C. The estimated time to complete this activity is 4.5 hours. 

Date of Release  
This activity was released on February 20, 2012. It is available for CME credit until February 20, 2015.

Course Objectives
Upon completion of this activity, the participant should be able to:

  • Identify the scientific basis for choice of immunogically-related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and HIV
  • Explain the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice including, anti-cytokine therapy, costimulatory blockade, lymphocyte depletion, adhesion-molecule blockade, and signaling/lymphocyte activation blockade
  • Evaluate the track record of the different therapeutic approaches in different specialties
  • Recognize the cross-disciplinary lessons that can be learned from the clinical experience with specific interventions including pharmacological issues, limitations in altering disease progression and complications due to immunosuppression (infections, neoplasias)
  • Analyze how a physician should decide to use and choose therapies

Course Content

  • The Immunologic Basis of Multiple Sclerosis and New Therapeutic Targets - Amit Bar-Or, MD, Montreal Neurological Institute
  • Targeting B Cells in SLE - John Looney, MD, University of Rochester
  • The Next Generation of TNF Inhibitors - Leonard Calabrese, DO, Cleveland Clinic Foundation
  • Advances in the Pathogenesis of the Spondyloarthopathies: Therapeutic Implications - Chris Ritchlin, MD, University of Rochester
  • Targeting the IL-12/23 Th17 Pathway in Psoriasis - James Krueger, MD, PhD, Rockefeller University
  • New Agents in Inflammatory Bowel Disease - Scott Plevy, MD, University of North Carolina at Chapel Hill

The Federation of Clinical Immunology Societies is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education credits for physicians.

The Federation of Clinical Immunology Societies designates this educational activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Faculty Disclosures

  • Amit Bar-Or, MD - Consultant/Advisor: Bayer, Bayhill Therapeutics, Berlex, Biogen Idec, BioMS, Diogenix, Eli Lilly, Genentech, GSK, Guthy/Jackson GGF, Teva Neuroscience, Wyeth, German Federal MS Kompetenz Network; Lecture fees: Bayhill Therapeutics, Berlex, Biogen Idec, Eli Lilly, Genentech; Grant Support: Biogen Idec, Genentech, Teva Neuroscience, Canadian Institutes of Health Research, Canadian Commercialization Research, Multiple Sclerosis Society of Canada, National Institutes of Health/Immune Tolerance Network
  • Leonard Calabrese, DO - Consultant/Advisor & Lecture Fees: Amgen, Abbott, Centocor, UCB, Roche, Genentech
  • James Krueger, MD, PhD - Lecture fees: Janssen-Ortho Centocor; Consultant/Advisor: Pfizer/Wyeth, Amgen, Eli Lilly, Novartis
  • John Looney, MD - Consultant/Advisor: Genentech, Millennium
  • Scott Plevy, MD - Advisory Committee: Abbott Immunology, Anaphore, Inc., BMS, CalciMedica, Inc., Centocor, DeNovo Therapetuics, Elan Pharmaceuticals, Eli Lilly, Flexicon, Genentech, GSK, Implicit Bioscience, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pharmacyclics, Proctor & Gamble, Synergy Pharmaceuticals, UCB, Unity Pharmaceuticals; Scientific Advisory Board: enGene, Inc., Protagonist Therapeutics, Inc., Synergy Pharmaceuticals; Grant Support: Genentech, Inc., Merck; Royalties: Prometheus Labs; Honoraria: Abbott Immunology, Centocor, Inc., UCB
  • Chris Ritchlin, MD - Consultant/Advisor: Abbott, Amgen, Centocor, UCB, Pfizer; Grant Support: Abbott, Centocor, UCB, Pfizer

This course was supported by unrestricted educational grants from Abbott, Janssen and Pfizer.

Questions? Please contact This email address is being protected from spambots. You need JavaScript enabled to view it. for more information.